Zuberbier T
Department of Dermatology and Allergy, University Hospital Charité, Humboldt University, Berlin, Germany.
Allergy. 2003 Dec;58(12):1224-34. doi: 10.1046/j.1398-9995.2003.00327.x.
Urticaria has been known as a disease since antiquity. However, in the last decades an increasing understanding of the mechanisms involved in its pathogenesis has shown the high heterogeneity of different urticaria subtypes. Clear distinction of the subtypes is required not only to choose the correct measures in diagnosis and management, but also to interpret the available data in research. The subtypes can be grouped into spontaneous urticaria, which includes acute urticaria and chronic urticaria, the physical urticarias, special types of urticaria including, e.g. contact urticaria, and diseases related to urticaria for historical reasons, e.g. urticaria pigmentosa. Most urticaria subtypes have a profound impact on the quality of life and effective treatment is thus required in case the diagnostic procedures do not reveal a cause which can be treated. Although, for symptomatic relief, nonsedating H1-antihistamines are the first choice in most subtypes of urticaria, double-blind controlled studies have shown that dosages required may exceed those recommended for other diseases, e.g. allergic rhinitis. Alternative treatments should be reserved for unresponsive patients.
自古以来,荨麻疹就被视为一种疾病。然而,在过去几十年里,人们对其发病机制的认识不断加深,这表明不同类型的荨麻疹具有高度的异质性。不仅在诊断和治疗中选择正确的措施需要明确区分这些亚型,而且在研究中解释现有数据时也需要这样做。这些亚型可分为自发性荨麻疹,包括急性荨麻疹和慢性荨麻疹;物理性荨麻疹;特殊类型的荨麻疹,如接触性荨麻疹;以及由于历史原因与荨麻疹相关的疾病,如色素性荨麻疹。大多数荨麻疹亚型对生活质量有深远影响,因此,如果诊断程序未能揭示可治疗的病因,就需要进行有效治疗。虽然在大多数荨麻疹亚型中,非镇静性H1抗组胺药是缓解症状的首选药物,但双盲对照研究表明,所需剂量可能超过针对其他疾病(如过敏性鼻炎)推荐的剂量。替代治疗应保留给无反应的患者。